Nitrofurantoin + Nitrofurantoin Microcrystals interactions

Checked as Nitrofurantoin in this data source.

Full monograph for Nitrofurantoin + Nitrofurantoin Microcrystals Check it against another medicine

Medicines

438 documented

Severity

Mechanism

Medicines documented to interact with Nitrofurantoin + Nitrofurantoin Microcrystals, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Articaine Hydrochloride + Epinephrine Bitartrate	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine	Major	Synergy · Unknown	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms	9 sources — open the full entry
Benzocaine + Butamben + Tetracaine Hydrochloride	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms	12 sources — open the full entry
Betamethasone + Phenylephrine + Lignocaine	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Bupivacaine Hydrochloride	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Bupivacaine Hydrochloride + Dextrose	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Calcium Dobesilate + Lidocaine + Dexamethasone	Major	Synergy · Unknown	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms	5 sources — open the full entry
Chloramphenicol + Lidocaine Hydrochloride	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms	9 sources — open the full entry
Diclofenac Sodium + Lidocaine Hydrochloride	Major	Synergy · Unknown	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms	5 sources — open the full entry
Hydrocortisone + Lidocaine	Major	Synergy · Unknown	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms	5 sources — open the full entry
Leflunomide	Major	Synergy	The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may…	3 sources — open the full entry
Lidocaine + Adrenaline	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Lidocaine + Epinephrine	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Lidocaine + Prilocaine	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms	18 sources — open the full entry
Lidocaine HydrochlorideInjection Spray	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Ofloxacin + Clotrimazole + Beclomethasone + Lidocaine	Major	Synergy · Unknown	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms	5 sources — open the full entry
Ropivacaine Hydrochloride	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Tolperisone + Lidocaine	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Tropicamide + Phenylephrine + Lidocaine	Major	Synergy	Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…	5 sources — open the full entry
Adalimumab	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Amiodarone Hydrochloride	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Amlodipine Besilate + Atorvastatin	Moderate	Synergy · Unknown	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms	4 sources — open the full entry
Atorvastatin + Ezetimibe	Moderate	Synergy · Unknown	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms	4 sources — open the full entry
Atorvastatin Calcium	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Bortezomib	Moderate	Synergy	Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or…	4 sources — open the full entry
Cabazitaxel	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Carbidopa + LevodopaExtended release Prolonged release	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Carboplatin	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Carfilzomib	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Chloramphenicol (Oral)	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Chloroquine Phosphate	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Cinchocaine + Hydrocortisone + Framycetin + Esculin	Moderate	Synergy · Unknown	Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…2 documented mechanisms	7 sources — open the full entry
Cinchocaine + Hydrocortisone + Neomycin + Esculin	Moderate	Synergy · Unknown	Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…2 documented mechanisms	7 sources — open the full entry
Cisplatin	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Colchicine	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Crizotinib	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Cyproterone Acetate + Ethinyl Estradiol	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Dapsone	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Dexamethasone + Chloramphenicol	Moderate	Synergy · Unknown	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms	4 sources — open the full entry
Dienogest + Estradiol Valerate	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Docetaxel Trihydrate	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Drospirenone + Estradiol	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg 0.03 mg	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Drospirenone + Ethinyl Estradiol + Levomefolate	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Efavirenz	Moderate	Synergy	Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with…	7 sources — open the full entry
Epirubicin Hydrochloride	Moderate	Synergy	The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes…	4 sources — open the full entry
Eribulin Mesylate	Moderate	Synergy	The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…	4 sources — open the full entry
Estradiolbase vaginal cream	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Estradiol + Dydrogesterone	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Estradiol Hemihydrate + Progesterone Micronized	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry

Conditions

Conditions in which Nitrofurantoin + Nitrofurantoin Microcrystals needs care, as documented in this source.

Colitis
Major
Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.
31 sources
1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
Show all 31 sourcesShow fewer sources
1. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
2. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
3. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
4. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
5. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
6. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
7. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
8. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
9. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
10. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
11. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
12. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
13. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
14. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
15. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
16. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
17. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
18. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
19. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
20. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
21. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
22. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
23. "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):
Glucosephosphate Dehydrogenase Deficiency
Major
Hemolytic anemia has been reported in patients treated with nitrofurantoin, primarily in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Therapy with nitrofurantoin should be avoided or administered cautiously in patients with G-6-PD deficiency. The development of hemolysis is an indication for withdrawal of nitrofurantoin therapy. Hemolysis ceases when the drug is withdrawn.
2 sources
1. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
2. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
Kidney Diseases
Major
The use of nitrofurantoin is contraindicated in patients with anuria, oliguria, or significant renal impairment (CrCl < 60 mL/min). Urinary concentration of the drug is likely to be inadequate in these patients, increasing the risk of therapeutic failure. Since nitrofurantoin is eliminated by the kidney, risk of toxicity may also be increased.
6 sources
1. Sachs J, Geer T, Noell P, Kunin CM "Effect of renal function on urinary recovery of orally administered nitrofurantoin." N Engl J Med 278 (1967): 1032-5
2. Hoener B, Patterson SE "Nitrofurantoin disposition." Clin Pharmacol Ther 29 (1981): 808-16
3. Schirmeister J, Stefani F, Willmann H, Hallauer W "Renal handling of nitrofurantoin in man." Chemotherapy 5 (1965): 223-6
4. Goff JB, Schlegel JU, O'Dell RM "Urinary excretion of nalidixic acid, sulfamethizole and nitrofurantoin in patients with reduced renal function." J Urol 99 (1968): 371-5
5. Glascock HW, Jr "Nitrofurantoin in renal failure." Ann Intern Med 69 (1968): 1077
6. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
Liver Diseases
Major
The use of nitrofurantoin has rarely been associated with hepatotoxicity, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis. Nitrofurantoin macrocrystals capsules are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. Most acute reactions are self-limiting and resolve spontaneously, although fatalities have been reported. Therapy with nitrofurantoin should be administered cautiously in patients with liver disease. Periodic monitoring of liver function is recommended during prolonged therapy. The drug should be withdrawn immediately if hepatitis or liver damage occurs and is felt to be drug-related. Since nitrofurantoin is partially metabolized by the liver, a reduced dosage may also be necessary to prevent toxicity.
14 sources
1. Reinhart HH, Reinhart E, Korlipara P, Peleman R "Combined nitrofurantoin toxicity to liver and lung." Gastroenterology 102 (1992): 1396-9
2. Stricker BH, Blok AP, Claas FH, Van Parys GE, Des Met VJ "Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases." Hepatology 8 (1988): 599-608
3. Maskell R "Nitrofurantoin induced chronic liver disease." J Antimicrob Chemother 19 (1987): 140
4. Thuluvath PJ, McKendrick MW "Nitrofurantoin induced chronic liver disease." J Antimicrob Chemother 18 (1986): 291-2
5. Miller AR, Addis BJ, Clarke PD "Nitrofurantoin and chronic active hepatitis." Ann Intern Med 97 (1982): 452
6. Sharp JR, Ishak KG, Zimmerman HJ "Chronic active hepatitis and sever heptic necrosis associated with nitrofurantoin." Ann Intern Med 92 (1980): 14-9
7. Black M, Rabin L, Schatz N "Nitrofurantoin-induced chronic active hepatitis." Ann Intern Med 92 (1980): 62-4
8. Hoener B, Patterson SE "Nitrofurantoin disposition." Clin Pharmacol Ther 29 (1981): 808-16
Show all 14 sourcesShow fewer sources
1. Mollison LC, Angus P, Richards M, Jones RM, Ireton J "Hepatitis due to nitrofurantoin." Med J Aust 156 (1992): 347-9
2. Sippel PJ, Agger WA "Nitrofurantoin-induced granulomatous hepatitis." Urology 18 (1981): 177-8
3. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
4. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
5. Mulberg AE, Bell LM "Fatal cholestatic hepatitis and multisystem failure associated with nitrofurantoin." J Pediatr Gastroenterol Nutr 17 (1993): 307-9
6. Burgert SJ, Burke JP, Box TD "Reversible nitrofurantoin-induced chronic active hepatitis and hepatic cirrhosis in a patient awaiting liver transplantation." Transplantation 59 (1995): 448-9
Peripheral Nervous System Diseases
Moderate
The use of nitrofurantoin has occasionally been associated with the development of peripheral neuropathy, which may be severe and irreversible. Patients at risk include the elderly and those with renal impairment, anemia, diabetes mellitus, electrolyte imbalance, vitamin B12 deficiency, diabetes, and/or debilitating diseases. Therapy with nitrofurantoin should be administered cautiously in patients with one or more risk factors and/or preexisting peripheral neuropathy. Periodic monitoring of renal function is recommended during prolonged therapy.
3 sources
1. White WT, Harrison L, Dumas J "Nitrofurantoin unmasking peripheral neuropathy in a type 2 diabetic patient." Arch Intern Med 144 (1984): 821
2. Yiannikas C, Pollard JD, McLeod JG "Nitrofurantoin neuropathy." Aust N Z J Med 11 (1981): 400-5
3. Craven RS "Furadantin neuropathy." Aust N Z J Med 3 (1971): 246-9
Respiratory Insufficiency
Moderate
Chronic pulmonary reactions, generally in patients who have received continuous treatment for 6 months or longer have been reported with the use of nitrofurantoin. Caution is recommended when prescribing this agent to patients with pulmonary dysfunction.
2 sources
1. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
2. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):

Therapeutic duplication

Drug classes that overlap with Nitrofurantoin + Nitrofurantoin Microcrystals, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

urinary anti-infectives
The recommended maximum number of medicines in the 'urinary anti-infectives' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'urinary anti-infectives' category.
Example product in the source data (US market): Urolet mb
urinary anti-infectives
The recommended maximum number of medicines in the 'urinary anti-infectives' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'urinary anti-infectives' category.
Example product in the source data (US market): Phosphasal
urinary anti-infectives
The recommended maximum number of medicines in the 'urinary anti-infectives' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'urinary anti-infectives' category.
Example product in the source data (US market): Prosed ds

Medicines

Conditions

Colitis

Glucosephosphate Dehydrogenase Deficiency

Kidney Diseases

Liver Diseases

Peripheral Nervous System Diseases

Respiratory Insufficiency

Therapeutic duplication

urinary anti-infectives

urinary anti-infectives

urinary anti-infectives